A recent article published by the Federal Register details updates to the Mandatory Guidelines for Federal Workplace Drug Testing Programs, issued by the Department of Health and Human Services (HHS). These updates revise the drug testing panels for urine and oral fluid and introduce new nomenclature for laboratory and Medical Review Officer reports. The changes include the addition of fentanyl and its metabolite, norfentanyl, to the authorized testing panels for urine and oral fluid, reflecting growing concerns about the opioid crisis. However, proposed removals of methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) were postponed for further review. Effective July 7, 2025, these updates aim to enhance the reliability, accuracy, and relevance of federal drug testing programs.
The revisions were informed by public comments, expert input, and emerging data, highlighting fentanyl’s increasing prevalence in workplace drug testing and public health concerns. Updated cutoffs for initial and confirmatory tests aim to align with technological capabilities and scientific findings. Additionally, HHS clarified that biomarkers for Federal workplace drug testing have not been approved yet, and further developments in this area will follow future evaluations.
Keele Medical remains at the forefront of innovation, incorporating fentanyl detection into its comprehensive drug panels alongside 27 additional drugs and alcohol. This proactive approach positions Keele Medical as a leader in delivering advanced, reliable testing solutions that align with evolving industry standards. With a commitment to accuracy and efficiency, Keele Medical provides essential tools to support workplace and law enforcement efforts in promoting safety and accountability.
